A phase one, open label, single arm study to demonstrate the safety of the Antria cell preparation process during facial fat grafting assisted with autologous, adipose-derived stromal vascular fraction (SVF)

Shah Rahimian
Antria, Inc., USA

Antria cell preparation process and it's special reagent Adiployx may display a safe method of supplementing traditional lipografts with adipose-derived stromal vascular fractions (SVFs), which can be utilized in cosmetic applications or therapeutic applications. Autologous transplantation of adipose tissue is a common treatment for facial lipoatrophy; however, treatment-result inconsistencies, regarding the sustainability of the adipose engraftment, require identification of a more efficacious treatment option according to Ersek et al. (1998) and Shiffman et al. (2001). In addition, facial lipoatrophy has been treated utilizing dermal fillers; however, dermal fillers are a less advantageous treatment option due to composite deterioration. Moreover, dermal fillers may induce allergic responses, skin depigmentation, and/or nasolabial folds according to Lowe et al. (2001).

Cellular components of the SVF have shown to secrete various growth factors that sustain the lipograft. Imperative to the function of SVF, in conjecture with lipoaspirate, is believed to be adipose-derived stem cells (ADSCs). According to Puglisi et al. (2010), Ichim et al. (2011), and Lu et al. (2011), ADSCs possess the ability to differentiate into various tissue types, inhibit inflammation, and stimulate angiogenesis. Thus, the proprietary reagent and the methodology of extracting and integrating the SVF with adipose tissue utilized in transplantation may enhance graft retention. Ergo, Antria will analyze the safety of SVF use in facial fat grafting via targeted physical examinations, laboratory assessments and long term follow ups up to 36 months post-op.

Antria has recently gained FDA and IRB approval to conduct a phase I study, within the United States, verifying the safety of SVF-enhanced lipografts within human subjects. Six subjects will be enrolled. Analysis of the resultant data, documenting Antria cell preparation process is a safe form of treatment, will be available at time of presentation.

Biography
Shah Rahimian graduated medical school from the University of Istanbul in 2000 where he subsequently pursued and later received his Ph.D. in Public Health. In the last 10 years, he has served as a senior scientist and general surgeon at Istanbul University, Vice President and Director of clinical research at Ilumina Clinical Associates, and a consultant for the biomedical industry throughout North America, Asia and Europe. Currently, he is dedicated to move forward with the mission of Antria, which is to treat patients suffering from rare and common diseases using cell-based therapies. His past medical background and expertise will place the clinical research organization at the forefront of utilizing emerging therapeutic treatments in the field of regenerative medicine.

srahimian@antria.org